JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This ...

Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental The U.S. Food and Drug Administration (FDA) ...

The FDA has approved Novavax’s protein-based COVID-19 vaccine, giving some Americans another option besides messenger RNA vaccines to prevent SARS-CoV-2 infection.

The U.S. Food and Drug Administration (FDA) has granted full approval to Novavax's COVID-19 vaccine, but only for certain ...

The FDA has approved Novavax’s COVID-19 vaccine, Nuvavoxid, for use in adults 65 and older and in individuals ages 12-64 who have at least one underlying health condition. The approval is based on ...

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

WASHINGTON — Robert F. Kennedy Jr. clinched the political support needed to become the nation’s top health official by ...

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...

Tesla's Chinese rival Xiaomi announced its electric SUV set to compete with Tesla's Model Y will be launched Thursday. TXNM ...

Novavax had expected full approval for broader use by April 1, after the FDA reviewed data from a 30,000-person clinical ...

In the options pits, NVAX has already seen quadruple the overall options volume it typically sees in an entire session, with ...